Last updated
4-HO-MALT structure.png
  • 3-[2-[methyl(prop-2-enyl)amino]ethyl]-1H-indol-4-ol
PubChem CID
Chemical and physical data
Formula C14H18N2O
Molar mass 230.311 g·mol−1
3D model (JSmol)
  • CN(CCC1=CNC2=C1C(=CC=C2)O)CC=C
  • InChI=1S/C14H18N2O/c1-3-8-16(2)9-7-11-10-15-12-5-4-6-13(17)14(11)12/h3-6,10,15,17H,1,7-9H2,2H3

4-HO-MALT (4-hydroxy-N-methyl-N-allyltryptamine) is a tryptamine derivative which has been sold as a designer drug, first being detected in Slovenia in 2021. [1] [2]

See also

Related Research Articles

5-Methoxy-<i>N</i>,<i>N</i>-diisopropyltryptamine Psychedelic tryptamine

5-Methoxy-N,N-diisopropyltryptamine is a psychedelic tryptamine and the methoxy derivative of diisopropyltryptamine (DiPT).

<span class="mw-page-title-main">4-HO-DiPT</span> Chemical compound

4-Hydroxy-N,N-diisopropyltryptamine is a synthetic psychedelic drug. It is a higher homologue of psilocin, 4-HO-DET, and is a positional isomer of 4-HO-DPT and has a tryptamine molecular sub-structure.

<span class="mw-page-title-main">Diisopropyltryptamine</span> Chemical compound

Diisopropyltryptamine is a psychedelic hallucinogenic drug of the tryptamine family that has a unique effect. While the majority of hallucinogens affect the visual sense, DiPT is primarily aural.

<span class="mw-page-title-main">5-MeO-MiPT</span> Chemical compound

5-MeO-MiPT is a psychedelic and hallucinogenic drug, used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a "substitute" for 5-MeO-DiPT because of the very similar structure and effects.

<span class="mw-page-title-main">4-HO-MiPT</span> Chemical compound

4-HO-MiPT is a synthetic substituted aromatic compound and a lesser-known psychedelic tryptamine. It is thought to be a serotonergic psychedelic, similar to magic mushrooms, LSD and mescaline. Its molecular structure and pharmacological effects somewhat resemble those of the tryptamine psilocin, which is the primary psychoactive chemical in magic mushrooms.

<span class="mw-page-title-main">4-MeO-MiPT</span> Chemical compound

4-MeO-MiPT, or 4-methoxy-N-methyl-N-isopropyltryptamine, is a lesser-known psychedelic drug. It is the 4-methoxy analog of MiPT. 4-MeO-MiPT was first synthesized by Alexander Shulgin and is mentioned in his book TiHKAL. Subsequent testing by Shulgin on human test subjects showed the effective dose as 20-30 mg ; the onset time between ingestion and the first noticeable effects was 45-60 min, with sensations lasting between 2-2.5 hours. The sensation were significantly milder than those of 4-HO-MiPT, with 4-MeO-MiPT producing erotic-enhancing effects, and few of the visuals common with tryptamines. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-MeO-MiPT.

<span class="mw-page-title-main">4-HO-DSBT</span> Chemical compound

4-HO-DsBT (4-hydroxy-N,N-di-sec-butyltryptamine) is a tryptamine derivative which acts as a serotonin receptor agonist. It was first made by Alexander Shulgin and is mentioned in his book TiHKAL, but was never tested by him. However it has subsequently been tested in vitro and unlike the n-butyl and isobutyl isomers which are much weaker, the s-butyl derivative retains reasonable potency, with a similar 5-HT2A receptor affinity to MiPT but better selectivity over the 5-HT1A and 5-HT2B subtypes.

<span class="mw-page-title-main">5-HO-DiPT</span>

5-HO-DiPT (5-hydroxy-N,N-di-iso-propyltryptamine) is a tryptamine derivative which acts as a serotonin receptor agonist. It is primarily known as a metabolite of the better known psychoactive drug 5-MeO-DiPT, but 5-HO-DiPT has also rarely been encountered as a designer drug in its own right. Tests in vitro show 5-HO-DiPT to have high 5-HT2A affinity and good selectivity over 5-HT1A, while being more lipophilic than the related drug bufotenine (5-HO-DMT), which produces mainly peripheral effects.

<span class="mw-page-title-main">5-MeO-DiBF</span> Chemical compound

5-MeO-DiBF is a psychedelic that has been sold online as a designer drug and was first definitively identified in December 2015 by a forensic laboratory in Slovenia. It is thought to act as an agonist for the 5-HT1A and 5-HT2 family of serotonin receptors. It is related in structure to the psychedelic tryptamine derivative 5-MeO-DiPT, but with the indole nitrogen replaced by oxygen, making 5-MeO-DiBF a benzofuran derivative. It is several times less potent as a serotonin agonist than 5-MeO-DiPT and with relatively more activity at 5-HT1A, but still shows strongest effects at the 5-HT2 family of receptors. LEGAL STATUS. It is not controlled under the 1971 Convention on Psychotropic Substances, so thus it has a legal grey area in many countries of the world, but its consumption still could be persecuted under severe analogue acts or the intend of sell to human consumption.

<span class="mw-page-title-main">5-MeO-MALT</span> Chemical compound

5-MeO-MALT (5-methoxy-N-methyl-N-allyltryptamine) is a lesser-known psychedelic drug that is closely related to 5-MeO-DALT and has been sold online as a designer drug.

<span class="mw-page-title-main">4-HO-McPT</span> Chemical compound

4-HO-McPT (4-hydroxy-N-methyl-N-cyclopropyltryptamine) is a psychedelic tryptamine derivative. It has serotonergic effects, and has reportedly been sold as a designer drug since around 2016, but was not definitively identified by forensic laboratories until 2018. It is illegal in Finland.

<span class="mw-page-title-main">5-MeO-EPT</span>

5-MeO-EPT is a psychedelic tryptamine derivative which has been sold as a designer drug.

<span class="mw-page-title-main">4-PrO-DMT</span> Chemical compound

4-Propionoxy-N,N-dimethyltryptamine is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is theorized to act as a prodrug for psilocin. It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019.

<span class="mw-page-title-main">Hydroxetamine</span>

Hydroxetamine is a recreational designer drug from the arylcyclohexylamine family, with dissociative effects. It is known as an active metabolite of the dissociative designer drug methoxetamine, but has also been sold in its own right since late 2019.

<span class="mw-page-title-main">5-MeO-MET</span> Chemical compound

5-MeO-MET (5-Methoxy-N-methyl-N-ethyltryptamine) is a relatively rare designer drug from the substituted tryptamine family, related to compounds such as N-methyl-N-ethyltryptamine and 5-MeO-DMT. It was first synthesised in the 1960s and was studied to a limited extent, but was first identified on the illicit market in June 2012 in Sweden. It was made illegal in Norway in 2013, and is controlled under analogue provisions in numerous other jurisdictions.

<span class="mw-page-title-main">5-MeO-DBT</span> Chemical compound

5-MeO-DBT is a rare substituted tryptamine derivative, which is thought to be a psychoactive substance and was identified in a designer drug sample by a forensic laboratory in Slovenia in March 2021, although only analytical studies have been conducted and no pharmacological data is available. It is nevertheless controlled under drug analogue legislation in a number of jurisdictions.

<span class="mw-page-title-main">MALT (psychedelic drug)</span>

MALT is a lesser-known drug from the tryptamine family. It is a novel compound with very little history of human use. It is closely related to methylpropyltryptamine (MPT), as well as N-methyltryptamine. It has been sold online as a designer drug. Very little information on the pharmacology or toxicity of MALT is available.

<span class="mw-page-title-main">Acetoxymethylketobemidone</span> Chemical compound

Acetoxymethylketobemidone (O-AMKD), is an opioid designer drug related to ketobemidone, with around the same potency as morphine. It was first identified in Germany in October 2020.

<span class="mw-page-title-main">4-HO-PiPT</span>

4-Hydroxy-N-propyl-N-isopropyltryptamine is a substituted tryptamine derivative which is claimed to have psychedelic effects. It has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.


  1. Klein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, Halberstadt AL (April 2021). "Investigation of the Structure-Activity Relationships of Psilocybin Analogues". ACS Pharmacology & Translational Science. 4 (2): 533–542. doi:10.1021/acsptsci.0c00176. PMC   8033608 . PMID   33860183.
  2. New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System (PDF). European Monitoring Centre for Drugs and Drug Addiction. June 2022. doi:10.2810/882318. ISBN   978-92-9497-737-3.